Table 2. Demographic features and treatment of study participants.
| Variables | AAV (n=30) | Type 1 AIH (n=12) | UC (n=19) | P |
|---|---|---|---|---|
| Age, years | 55.7±11.5 | 40.8±19.3 | 46.3±18.2 | 0.013 |
| Females, n (%) | 18 (60.0) | 12 (100.0) | 15 (78.9) | 0.024 |
| Time since diagnosis, months | 47.5 (18.5-96.0) | 108.0 (72.0-132.0) | 84.0 (43.0-168.0) | 0.016 |
| Therapies | ||||
| Prednisone, n (%) | 18 (60.0) | 5 (41.7) | 2 (7.8) | 0.003 |
| Prednisone, mg/day | 15.0 (5.0-30.0) | 10.0 (10.0-15.0) | 30.0 (20.0-40.0) | 0.467 |
| Mesalazine, n (%) | 0 | 0 | 13 (68.4) | NA |
| Immunosuppressive agents, n (%) | 13 (43.3) | 10 (83.3) | 3 (15.7) | 0.001 |
| Azathioprine, n (%) | 4 (13.3) | 9 (75.0) | 3 (15.7) | NA |
| Methotrexate, n (%) | 3 (10.0) | 0 | 0 | NA |
| Oral cyclophosphamide, n (%) | 3 (10.0) | 0 | 0 | NA |
| iv Cyclophosphamide, n (%) | 2 (6.6) | 0 | 0 | NA |
| Leflunomide, n (%) | 1 (3.3) | 0 | 0 | NA |
| Mycophenolate sodium, n (%) | 0 | 1 (8,3) | 0 | NA |
| Biologic agents, n (%) | 5 (16.7) | 1 (8.3) | 4 (21.1) | 0.647 |
| Rituximab, n (%) | 5 (16.7) | 0 | 0 | NA |
| TNFα antagonists, n (%) | 0 | 1 (8.3) | 4 (21.1) | NA |
AAV: ANCA-associated vasculitis; AIH: autoimmune hepatitis; UC: ulcerative colitis; iv: intravenous; n: number of patients; NA: not applicable; TNF: tumor necrosis factor. Comparisons between categorical variables were made with the chi-squared test and Fisher's exact test. Continuous variables were compared between three groups with one-way ANOVA or Kruskal-Wallis test.